Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

GlycoBoost Precision control of glycosylation to open a new era of therapeutic antibodies

Coordinator
Kyron.bio, France
Runs
1 April 2025 to 30 September 2027
Status
Running
EU funding
€2.5m
Total cost
—
Partners
2 organisations in 2 countries
Type
European Innovation Council
Grant agreement
101214245

What the project is doing

In the project's own words, from its summary on CORDIS.

​​Biologics comprise a $511B market of advanced therapeutics that are used to treat cancer, autoimmune diseases, infectious diseases and beyond. Two thirds of biologics are decorated with sugar molecules attached to the therapeutics, including all antibody therapeutics, called monoclonal antibodies (mAbs). These sugar molecules are known as N-glycans and are vitally important for therapeutic safety and efficacy. To date, the N-glycans are poorly controlled and, as such, display highly heterogeneous patterns on a therapeutic.

This complicates large-scale production and regulatory approval of biologics, and significantly limits the possibility of using N-glycans in therapeutic design. GlycoBoost revolutionises mAb design by delivering consistent N-glycans, precisely profiled with advanced analytical techniques. This innovation unlocks the full potential of N-glycans to elevate the effectiveness of mAbs. Kyron.bio’s breakthrough technology uses cell engineering to produce therapeutic proteins with uniform and precision-controlled N-glycan patterns.

This technology is being used to produce glycoengineered mAbs that are safer and more effective for patients, starting with mAbs used to treat autoimmune diseases where patient resistance to current treatments remains high. Through a well-established collaboration between kyron.bio and Genos, one of the world leaders in glycoanalytics on whose SYSCID project this proposal is built, GlycoBoost aims to advance the project to commercialisation through the development of advanced glycoanalytical techniques, preclinical evaluation, pre-industrialisation, bespoke customer PoC’s, partnership-building, and fundraising.

GlycoBoost will place Europe at the heart of the glycobiology revolution, leading to the development of safer and more effective treatments for autoimmune diseases and ultimately redefining the landscape of therapeutic drug development.

Topics

Who is involved

OrganisationCityCountryRole
Kyron.bioParisFranceCoordinator
Genos Doo Za Vjestacenje I AnalizuOsijekCroatiaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI